請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76712完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 方啟泰(Chi-Tai Fang) | |
| dc.contributor.author | Xiang-Ting Huang | en |
| dc.contributor.author | 黃湘婷 | zh_TW |
| dc.date.accessioned | 2021-07-10T21:35:30Z | - |
| dc.date.available | 2021-07-10T21:35:30Z | - |
| dc.date.copyright | 2020-09-10 | |
| dc.date.issued | 2020 | |
| dc.date.submitted | 2020-08-19 | |
| dc.identifier.citation | 衛生福利部疾病管制署. 衛生福利部疾病管制署組織與職掌/組織架構圖. 2020; Available from: https://www.cdc.gov.tw/CdcOrganization/Index/cBX61rWwT5TKpS7BbMzKag. 2. Creighton, C., A History of Epidemics in Britain: Volume 1. 1965. 3. WHO, Measles vaccines: WHO position paper – April 2017. Wkly Epidemiol Rec, 2017. 92(17): p. 205-27. 4. Strebel, W.J.M.a.P., Biological Feasibility of Measles Eradication. J Infect Dis, 2011. 204(Suppl 1): S47–S53. 5. Lara J Wolfson, P.M.S., Marta Gacic-Dobo, Edward J Hoekstra, Jeffrey W McFarland, Bradley S Hersh, Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. The Lancet, 2007. Volume 369, Issue 9557. 6. Secretariat, W., Global eradication of measles. SIXTY-THIRD WORLD HEALTH ASSEMBLY, 2010. 7. W.A. Orenstein, A.H., B. Nkowane, J.M. Olive, A. Reingold, Measles and Rubella Global Strategic Plan 2012–2020 midterm review. Vaccine, 2018. Volume 36, Supplement 1. 8. Patel, M.K., et al., The Changing Global Epidemiology of Measles, 2013–2018. The Journal of Infectious Diseases, 2020. 9. WHO, Measles (https://www.who.int/news-room/fact-sheets/detail/measles). 2020. 10. 林杜凌, et al., 2019年中部某醫院麻疹群聚事件調查. 疫情報導, 2019. 35(11): p. 140-145. 11. 賴淑寬, et al., 2019年一至五月臺灣麻疹疫情概況. 疫情報導, 2019. 35(11): p. 135-139. 12. 黃湘婷, et al., 2019年北部地區境外移入麻疹個案相關群聚感染事件調查. 疫情報導, 2020. 36(8): p. 111-116. 13. Huang, H.-I., et al., Measles transmission at an international airport — Taiwan, March–April 2018. International Journal of Infectious Diseases, 2019. 86: p. 188-190. 14. GIDEON Informatics, Measles Outbreaks (https://web.gideononline.com/web/epidemiology/index.php?country=OUTBREAK disease=11450 view=Distribution#). 15. WHO/Europe, European Region loses ground in effort to eliminate measles (https://www.euro.who.int/en/media-centre/sections/press-releases/2019/european-region-loses-ground-in-effort-to-eliminate-measles). 2019. 16. WHO, The immunological basis for immunization series : module 7: measles - Update 2009. 2009. 17. WHO, WHO Vaccine-Preventable Diseases Surveillance Standards. 2018: World Health Organization 18. WHO, Guide for clinical case management and infection prevention and control during a measles outbreak. 2020, Geneva: World Health Organization. 19. 李慶雲, et al., 麻疹現況. 疫情報導, 1985. 1(5): p. 33-34. 20. Helfand, R.F., et al., Nonclassic measles infections in an immune population exposed to measles during a college bus trip. J Med Virol, 1998. 56(4): p. 337-41. 21. Rota, J.S., et al., Two case studies of modified measles in vaccinated physicians exposed to primary measles cases: high risk of infection but low risk of transmission. J Infect Dis, 2011. 204 Suppl 1: p. S559-63. 22. Sundell, N., et al., Measles outbreak in Gothenburg urban area, Sweden, 2017 to 2018: low viral load in breakthrough infections. Eurosurveillance, 2019. 24(17): p. 1900114. 23. Woudenberg, T., The 2013-2014 measles outbreak in The Netherlands: New evidence on measles epidemiology and control. 2020, Utrecht University. 24. WHO, Manual for the laboratory diagnosis of measles and rubella infection. Second ed. 2007. 25. CDC), C.f.D.C.a.P.U., Recommendations from an ad hoc Meeting of the WHO Measles and Rubella Laboratory Network (LabNet) on use of alternative diagnostic samples for measles and rubella surveillance. MMWR Morb Mortal Wkly Rep, 2008. 57(24): p. 657-60. 26. WHO, Manual for the Laboratory-based Surveillance of Measles, Rubella, and Congenital Rubella Syndrome, ed. Third. 2018. 27. Lee MS1, K.C., Chen CJ, Yang SY, Ho MS., Epidemiology of Measles in Taiwan: Dynamics of Transmission and Timeliness of Reporting during an Epidemic in 1988-9. Epidemiol Infect, 1995 Apr. 114(2):345-59. 28. LEE, M.-S., et al., Seroepidemiology and Evaluation of Passive Surveillance during 1988–1989 Measles Outbreak in Taiwan. International Journal of Epidemiology, 1992. 21(6): p. 1165-1174. 29. Lee, M.-S., et al., Post mass-immunization measles outbreak in Taoyuan county, Taiwan: Dynamics of transmission, vaccine effectiveness, and herd immunity. International Journal of Infectious Diseases, 1999. 3(2): p. 64-69. 30. Cheng, W.Y., et al., Molecular evolution of measles viruses circulated in Taiwan 1992-2008. Virol J, 2009. 6: p. 219. 31. Ming-Been Lee, L.L.L., Hua Chen, Yuen-shing Wu, Cian-Ya Horng Post Mass-Immunization Measles Outbreak in Taoyuan County, Taiwan: Dynamics of Transmission, Vaccine Effectiveness, and Herd Immunity International journal of infectious diseases. Volume 3, Number 2, Winter 1998-1999 32. 行政院衛生署疾病管制局, 麻疹標準防治作業手冊. 中華民國九十四年十一月. 33. 行政院衛生署疾病管制局, 麻疹防治標準作業手冊. 中華民國 99 年 1 月. 34. 衛生署疾病管制局, 根除小兒麻痺、新生兒破傷風、先天性德國麻疹症候群及麻疹第四期計畫. 2006: 2006年4月. 35. Chiu, H.-H., et al., Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan. Journal of Medical Virology, 1997. 51(1): p. 32-35. 36. Lee, M.S., et al., Seroepidemiology and evaluation of passive surveillance during 1988-1989 measles outbreak in Taiwan. Int J Epidemiol, 1992. 21(6): p. 1165-74. 37. Fiona M Guerra, S.B., Gillian Lim, Jane Heffernan, Shelley L Deeks, Ye Li, Natasha S Crowcrof, The basic reproduction number (R0) of measles: a systematic review. The Lancet Infectious Diseases, 2017. 17(12): p. e420-e428. 38. Bart, K.J., et al., 根除三麻一風計畫-“麻疹、先天性德國麻疹症候群及新生兒破傷風之消除作業”評估. 疫情報導, 2010. 26(5): p. 60-73. 39. 衛生福利部疾病管制署, Measles cases and immunization coverage in Taiwan from 1986 to 2018. 2020. 40. 顏哲傑、鄭雯月、李佳琳, 台灣地區五十歲以下人口麻疹、德國麻疹與腮腺炎之血清流行病學調查研究, 衛生署疾病管制局, Editor. 2003. 41. Huang, C.L., et al., Humoral and cellular immune response after measles vaccination in Taiwan. J Microbiol Immunol Infect, 2005. 38(3): p. 169-75. 42. Chen, C.-J., et al., Waning population immunity to measles in Taiwan. Vaccine, 2012. 30(47): p. 6721-6727. 43. Lee, Y.-C., et al., Measles immunity gaps in an era of high vaccination coverage: A serology study from Taiwan. Travel Medicine and Infectious Disease, 2020. 36: p. 101804. 44. 衛生福利部疾病管制署, 麻疹疫調、接觸者追蹤管理及群聚事件處理原則. 2019. 45. 溫倩茹, et al., 台灣麻疹抗體盛行率,以民眾麻疹抗體檢驗調查為例. 台灣家庭醫學雜誌, 2019. 29(3): p. 124-131. 46. 黃立民, 黃玉成, and 黃瑽寧, 學童血清流行病學調查計畫. 2003, 行政院衛生署疾病管制局 102 年委託科技研究計畫. 47. Watanabe, A., et al., Correlates of laboratory-confirmed measles in Japan, 2011–2015. Vaccine, 2019. 37(13): p. 1756-1762. 48. Hayman, D.T.S., Measles vaccination in an increasingly immunized and developed world. Human Vaccines Immunotherapeutics, 2019. 15(1): p. 28-33. 49. Gibney, K.B., et al., Emergence of Attenuated Measles Illness Among IgG-positive/IgM-negative Measles Cases: Victoria, Australia, 2008-2017. Clin Infect Dis, 2020. 70(6): p. 1060-1067. 50. Kang, H.J., et al., An increasing, potentially measles-susceptible population over time after vaccination in Korea. Vaccine, 2017. 35(33): p. 4126-4132. 51. Cheng, W.Y., et al., Measles surveillance in Taiwan, 2012-2014: Changing epidemiology, immune response, and circulating genotypes. J Med Virol, 2016. 88(5): p. 746-53. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76712 | - |
| dc.description.abstract | 背景及目的: 2018及2019年全球多國爆發麻疹疫情,臺灣亦受國際疫情影響,確診病例超越過往數十年紀錄,本研究目的為探究臺灣麻疹政策推行40年後,對麻疹發生率之影響,進一步從確診個案流行病學與實驗室診斷資訊,找出罹病危險因子或個案特徵,提供臨床與公共衛生防治參考。 方法:本研究以衛生福利部疾病管制署「傳染病個案通報系統」中,於2002至2019年發病之麻疹確定病例進行回溯性世代研究(retrospective cohort study),並參考麻疹疫苗常規接種計畫分為3個世代,包含(1) Cohort A (1976年9月以前出生,非疫苗受惠世代)、(2) Cohort B (1976年9月-1990年9月出生,應接種2劑MV疫苗及1劑MMR疫苗),及(3) Cohort C (1990年9月以後出生,應接種2劑MMR接種)。基本人口學變項由「傳染病個案通報系統」資料取得,分析2018至2019年麻疹確定個案病程發展、疫苗接種史、接觸史、旅遊史等類別變項,進行卡方檢定或費雪精確性檢定。 結果:2002至2019年麻疹確定病例共計397例,其中以Cohort B(1976-1990年出生)且年齡介於18-39歲間病例最多(178人, 44.8%),為臺灣近18年麻疹防治負擔最大標的族群。另分析2018至2019年共計168名麻疹確定病例臨床表現,主要為發燒(89%)及紅疹(95%),但仍有49%無咳嗽、鼻炎或結膜炎等任一種症狀,紀錄有柯氏斑症狀比率偏低(8%)。83%病例源自境外移入及境外移入衍生群聚;60%為醫師通報、37%經過接觸者健康監測檢驗確診;51%麻疹確定病例經流行病學調查確認具有接觸史,發生場域包含醫療院所(23%)、國際機場及航空器(11%)等處。有近6成急性期血清抗體檢驗為IgM(-)/IgG(+),疑因疫苗保護力下降(waning immunity)產生之突破性感染,雖症狀較不典型,但仍有部分突破性感染者造成次波疫情發生。未接種疫苗幼兒感染後臨床表現接近原發性感染(primary infection)之典型症狀,為疫情高峰期間不明感染源比例較多之年齡層。 討論:臺灣為高麻疹疫苗接種率及低發生率國家,感染主因為年輕成人疫苗保護力下降產生之突破性感染、境外移入相關因素與接觸史。突破性感染者不易由臨床症狀進行鑑別診斷,建議醫護人員可透過了解患者病程及接觸史,同時進行麻疹分子生物及抗體檢驗,以及早診斷避免疫情傳播。另就日後臺灣成人MMR疫苗接種政策,可進一步評估是否針對不同疫苗接種政策受惠世代提出不同接種建議,如本研究發現1976年以後出生之年輕成人(以1981年以後出生者尤其重要),在出國前或國內發生本土麻疹疫情時,可建議補種1劑MMR疫苗,以增加群體免疫力。另外針對高風險職業,如醫療院所或國際機場工作者,亦可評估職前接種MMR疫苗,減少職業暴露風險。 | zh_TW |
| dc.description.abstract | Background: Measles has surged in 2018–2019, with large measles outbreaks around the world. Taiwan was also affected by the global outbreak. The confirmed cases exceeded the previous annual records. The study amid to explore the incidence rate for implementation of the prevention policy, and to further find out the risk factors or clinical characteristics of measles. Methods: We conducted a retrospective cohort study that enrolled the confirmed measles cases from 2002-2019 in national web-based Notifiable Diseases Surveillance System. Based on the national immunization program, the study were classified 3 cohort: Cohort A (born before Sep. 1976, pre-mass vaccination), Cohort B (born in Sep. 1976–Sep. 1990, 2 dose of MV and 1 dose of MMR) and Cohort C (born after Sep. 1990, at least 2 dose of MMR). We analyzed category variables such as demographic factor, clinical characteristics, vaccination history, contact history and travel history. The chi-squared test and fisher exact test were used to identify variables associated with different cohort. Results: There were 397 confirmed cases from 2002 through 2019, of which 44.8% where Cohort B and 18-38 years of age. In addition, we analyzed the clinical presentation of 168 confirmed cases from 2018 through 2019, fever (89%) and rash (95%) were the most common symptoms, and 49% didn't have the symptoms of cough, coryza, and conjunctivitis. According to epidemiological investigation, 83% were imported or importation-related cases, 51% had a record of a contact history, 23% cases occurred in healthcare-settings and 11% in international airport or airplane settings. Nearly 60% cases of the acute-phase serum antibody test was IgM(-)/IgG(+), suspected of breakthrough infection caused by reduced vaccine protection (waning immunity). Conclusion: Taiwan is a country with stronger measles historical vaccination programs and low incidence rate. The onset age shift to young adult, breakthrough infections were common. The findings of this study could improve the clinical diagnosis and decision making of vaccination programs. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-10T21:35:30Z (GMT). No. of bitstreams: 1 U0001-1808202023364300.pdf: 3521321 bytes, checksum: c57e5ad0c71b3180d08a1ee2cbba818d (MD5) Previous issue date: 2020 | en |
| dc.description.tableofcontents | 目錄 論文口試委員審定書 i 誌謝 ii 摘要 iii Abstract v 第一章 導論 1 1.1 實習單位簡介 1 1.2 文獻探討 2 1.2.1 全球及臺灣麻疹流行概況 2 1.2.2 麻疹臨床症狀與實驗室診斷 5 1.2.3 臺灣麻疹疾病監測、疫苗政策與歷年血清免疫調查結果 9 1.2.4 高收入國家麻疹感染危險因子 20 1.3 文獻回顧總結與實證缺口 22 1.4 研究目的與研究問題 25 第二章 研究方法 26 2.1 資料來源及研究對象 26 2.2 資料分析步驟 28 2.3 測量變項及重要變項定義 29 第三章 結果 32 3.1 2002年至2019年臺灣麻疹確定病例長期趨勢 32 3.2 2018年至2019年臺灣麻疹確定病例流行病學及臨床特徵 36 3.3 麻疹初次感染與疫苗失效感染個案特徵 45 第四章 討論 48 參考文獻 51 圖表目錄 圖 1、實習單位組織架構圖 1 圖 2、全球麻疹根除計畫推行時間與目標 2 圖 3、高收入國家2019年麻疹發生率及2014至2018年麻疹疫苗平均涵蓋率 4 圖 4、麻疹傳染性、臨床徵狀及實驗室診斷時序圖,WHO 2018 6 圖 5、麻疹急性感染免疫反應,WHO 2007 8 圖 6、臺灣不同出生世代麻疹疫苗接種政策及補種計畫 13 圖 7、1986至2018年臺灣麻疹病例數及疫苗接種涵蓋率 14 圖 8、資料分析流程圖 29 圖 9、指標個案與次波感染者之暴露期及可傳染期因果時序示意圖 32 圖 10、2002年至2019年臺灣麻疹確定個案(a)發生率及個案數(b)年齡層個案數(c)年齡層發生率 34 圖 11、2002年至2019年臺灣不同麻疹疫苗接種政策受惠世代發病情形(d)確定病例出生年代 (e)確定病例發病年代 (f)確定病例年齡層個案數及發生率 35 圖 12、2018年至2019年臺灣麻疹群聚事件指標個案「鼻咽拭子及尿液檢體CT值及次波感染確定病例數」;(g)為指標個案可傳染期採之檢體檢驗結果、(h)為超過指標個案可傳染期採檢之檢體檢驗結果 45 表 1、臺灣歷年麻疹通報條件及確定病例定義 11 表 2、臺灣歷年麻疹血清抗體調查結果-1 18 表 3、臺灣歷年麻疹血清抗體調查結果-2 19 表 4、臺灣歷年麻疹血清抗體調查結果-3 20 表 5、2002年至2019年臺灣不同麻疹疫苗接種政策受惠世代年齡層確診個案數及發生率 36 表 6、2018年至2019年不同疫苗政策受惠世代麻疹確定病例人口學、臨床表現及實驗室診斷特徵 39 表 7、2018年至2019年不同疫苗政策受惠世代麻疹確定病例流行病學及群聚特徵 42 表 8、2018年至2019年臺灣麻疹群聚事件指標個案特徵 44 表 9、2018年至2019年不同疫苗政策受惠世代及年齡分層之麻疹確定病例人口學、臨床表現及實驗室診斷特徵 48 表 10、2018年至2019年不同疫苗政策受惠世代麻疹及年齡分層確定病例流行病學及群聚特徵 49 | |
| dc.language.iso | zh-TW | |
| dc.subject | 突破性感染 | zh_TW |
| dc.subject | 麻疹疫苗 | zh_TW |
| dc.subject | 成人麻疹 | zh_TW |
| dc.subject | 實驗室診斷 | zh_TW |
| dc.subject | 世代效應 | zh_TW |
| dc.subject | 境外移入 | zh_TW |
| dc.subject | Laboratory diagnosis | en |
| dc.subject | Adult measles | en |
| dc.subject | MMR vaccine | en |
| dc.subject | Breakthrough infection | en |
| dc.subject | Imported cases | en |
| dc.subject | Cohort effect | en |
| dc.title | 2018至2019年臺灣麻疹流行病學及臨床特徵 | zh_TW |
| dc.title | Epidemiological and Clinical Characteristics of Measles cases/outbreaks in Taiwan, 2018-2019 | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 108-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 蘇韋如(Wei-Ju Su),呂俊毅(Chun-Yi Lu) | |
| dc.subject.keyword | 成人麻疹,麻疹疫苗,突破性感染,境外移入,世代效應,實驗室診斷, | zh_TW |
| dc.subject.keyword | Adult measles,MMR vaccine,Breakthrough infection,Imported cases,Cohort effect,Laboratory diagnosis, | en |
| dc.relation.page | 60 | |
| dc.identifier.doi | 10.6342/NTU202004044 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2020-08-19 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 公共衛生碩士學位學程 | zh_TW |
| 顯示於系所單位: | 公共衛生碩士學位學程 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-1808202023364300.pdf 未授權公開取用 | 3.44 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
